Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a full-year revenue forecast that fell short of analysts' estimates.

The pharmaceutical company's fourth-quarter sales grew 11.5% year-over-year to $814.3 million, and its adjusted profit of $0.21 per share surpassed market consensus. However, investors appeared to focus on the company's outlook. Amneal's full-year 2026 revenue guidance, with a midpoint of $3.1 billion, was 3.4% below what analysts had projected. This weaker-than-anticipated sales forecast overshadowed the solid quarterly performance and a beat on full-year profit guidance, raising concerns about the company's future growth trajectory.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Amneal? Access our full analysis report here, it’s free.

Amneal’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 4 months ago when the stock gained 8.9% on the news that the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast.

The pharmaceutical company posted adjusted earnings of $0.17 per share for the quarter, beating analyst estimates. Revenue also topped forecasts, reaching $785 million, which represented a 12% increase compared to the same period in the prior year. Bolstered by these results, Amneal provided an improved outlook for the full year. The company revised its projections for net revenue to a range between $3.0 billion and $3.1 billion and lifted its forecast for adjusted earnings per share to between $0.75 and $0.80.

Amneal is up 8.1% since the beginning of the year, but at $13.69 per share, it is still trading 9.9% below its 52-week high of $15.19 from February 2026. Investors who bought $1,000 worth of Amneal’s shares 5 years ago would now be looking at an investment worth $2,642.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.